WallStreetZenWallStreetZen

NASDAQ: CRVS
Corvus Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for CRVS

Based on 5 analysts offering 12 month price targets for Corvus Pharmaceuticals Inc

Min Forecast
$27.00+123.51%
Avg Forecast
$34.00+181.46%
Max Forecast
$42.00+247.68%

Should I buy or sell CRVS stock?

Based on 5 analysts offering ratings for Corvus Pharmaceuticals Inc.

Strong Buy
Strong Buy
3 analysts 60%
Buy
2 analysts 40%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although CRVS's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates CRVS as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their CRVS stock forecasts and price targets.

CRVS stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-04-17
lockedlocked$00.00+00.00%2026-03-13
lockedlocked$00.00+00.00%2026-01-22
lockedlocked$00.00+00.00%2026-01-21Find Out Why
lockedlocked$00.00+00.00%2026-01-20

1 of 1

Forecast return on equity

Is CRVS forecast to generate an efficient return?

Company
-9.8%
Industry
92.87%
Market
169.3%
CRVS's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is CRVS forecast to generate an efficient return on assets?

Company
-9.32%
Industry
27.75%
CRVS is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CRVS earnings per share forecast

What is CRVS's earnings per share in the next 3 years based on estimates from 9 analysts?

Avg 1 year Forecast
-$0.68
Avg 2 year Forecast
-$0.85
Avg 3 year Forecast
-$0.87

CRVS revenue forecast

What is CRVS's revenue in the next 3 years based on estimates from 8 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$8.6M
Avg 3 year Forecast
$43.7M

CRVS vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CRVS$12.08$34.00+181.46%Strong Buy
ABSI$6.52$8.75+34.20%Strong Buy
CGEM$16.21$33.60+107.28%Strong Buy
AKTS$19.48$31.50+61.70%Strong Buy
XERS$6.07$9.50+56.51%Strong Buy
View Top Biotech Stocks

Corvus Pharmaceuticals Stock Forecast FAQ

Is Corvus Pharmaceuticals Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NASDAQ: CRVS) stock is to Strong Buy CRVS stock.

Out of 5 analysts, 3 (60%) are recommending CRVS as a Strong Buy, 2 (40%) are recommending CRVS as a Buy, 0 (0%) are recommending CRVS as a Hold, 0 (0%) are recommending CRVS as a Sell, and 0 (0%) are recommending CRVS as a Strong Sell.

If you're new to stock investing, here's how to buy Corvus Pharmaceuticals stock.

What is CRVS's earnings growth forecast for 2026-2028?

(NASDAQ: CRVS) Corvus Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.93%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.26%.

Corvus Pharmaceuticals's earnings in 2026 is -$44,168,000.On average, 9 Wall Street analysts forecast CRVS's earnings for 2026 to be -$57,223,534, with the lowest CRVS earnings forecast at -$68,399,151, and the highest CRVS earnings forecast at -$45,030,422. On average, 9 Wall Street analysts forecast CRVS's earnings for 2027 to be -$71,804,813, with the lowest CRVS earnings forecast at -$92,297,649, and the highest CRVS earnings forecast at -$49,445,169.

In 2028, CRVS is forecast to generate -$73,192,305 in earnings, with the lowest earnings forecast at -$107,955,286 and the highest earnings forecast at -$14,127,191.

What is CRVS's revenue growth forecast for 2026-2028?

(NASDAQ: CRVS) Corvus Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.45%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.02%.

Corvus Pharmaceuticals's revenue in 2026 is $0.On average, 8 Wall Street analysts forecast CRVS's revenue for 2026 to be $0, with the lowest CRVS revenue forecast at $0, and the highest CRVS revenue forecast at $0. On average, 9 Wall Street analysts forecast CRVS's revenue for 2027 to be $724,270,822, with the lowest CRVS revenue forecast at $164,817,231, and the highest CRVS revenue forecast at $1,273,885,833.

In 2028, CRVS is forecast to generate $3,677,862,874 in revenue, with the lowest revenue forecast at $865,290,463 and the highest revenue forecast at $7,778,784,672.

What is CRVS's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: CRVS) forecast ROA is -9.32%, which is lower than the forecast US Biotechnology industry average of 27.75%.

What is CRVS's Price Target?

According to 5 Wall Street analysts that have issued a 1 year CRVS price target, the average CRVS price target is $34.00, with the highest CRVS stock price forecast at $42.00 and the lowest CRVS stock price forecast at $27.00.

On average, Wall Street analysts predict that Corvus Pharmaceuticals's share price could reach $34.00 by Apr 17, 2027. The average Corvus Pharmaceuticals stock price prediction forecasts a potential upside of 181.46% from the current CRVS share price of $12.08.

What is CRVS's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: CRVS) Corvus Pharmaceuticals's current Earnings Per Share (EPS) is -$0.52. On average, analysts forecast that CRVS's EPS will be -$0.68 for 2026, with the lowest EPS forecast at -$0.81, and the highest EPS forecast at -$0.54. On average, analysts forecast that CRVS's EPS will be -$0.85 for 2027, with the lowest EPS forecast at -$1.10, and the highest EPS forecast at -$0.59. In 2028, CRVS's EPS is forecast to hit -$0.87 (min: -$1.28, max: -$0.17).

What is CRVS's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: CRVS) forecast ROE is -9.8%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.